Amphista Therapeutics Enters Targeted Protein Degradation Partnership with Domainex

Published on: 

Amphista Therapeutics and Domainex will work together to develop treatments focusing on targeted protein degradation.

Amphista Therapeutics, a biotechnology company focusing on drug discovery projects that use targeted protein degradation (TPD), announced on Oct. 6, 2022, that it had selected Domainex, a medicines research service partner, as a partner to provide integrated drug discovery services for its research programs. Domainex will provide Amphista with expertise in protein production, assay biology, and medicinal chemistry.

According to a company press release, Domainex has experience designing, synthesizing, and profiling targeted heterobifunctional protein degraders. Additionally, the company has established in-vitro binary and ternary complex formation assays to confirm target engagement.

“We are delighted to have been selected by Amphista Therapeutics to help them advance their portfolio of drug discovery projects, building on our previous collaboration,” said Tom Mander, CEO, Domainex, in the release. “Our skilled, multi-disciplinary, integrated team of medicinal chemists, cell biologists, biophysicists, and protein scientists will work closely with the scientific leadership team at Amphista to advance their cutting-edge protein degrading technology.”


“Amphista is expanding rapidly as we advance our growing internal TPD portfolio and our recently signed research collaborations with BMS and Merck Healthcare,” said Nicki Thompson, CEO, Amphista, in the release. “To support our planned growth, we’re also excited to expand our network of contract research collaborators and work with Domainex with their high-quality chemistry, assay biology, [and] biophysical expertise as we tap into the rich expertise in the Cambridge, UK, area.”

Source: Domainex